These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 1426663

  • 1. Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
    Böhle A, Busemann E, Gerdes J, Ulmer AJ, Flad HD, Jocham D.
    Dev Biol Stand; 1992; 77():199-209. PubMed ID: 1426663
    [Abstract] [Full Text] [Related]

  • 2. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP.
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract] [Full Text] [Related]

  • 3. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 4. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

  • 5. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M, Oshiro Y, Hokama S, Sugaya K, Ogawa Y.
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [Abstract] [Full Text] [Related]

  • 6. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG, Gschwend JE, Maier SH, Seidl-Schlick EM, Bach D, Romics I.
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 10. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 11. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 12. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM, de Boer EC, Kurth KH, Schamhart DH.
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [Abstract] [Full Text] [Related]

  • 13. [Clinical experience with BCG immune prevention in superficial bladder cancer].
    Bach D, Romics I, Rüssel C.
    Urologe A; 1992 Sep; 31(5):296-301. PubMed ID: 1302409
    [Abstract] [Full Text] [Related]

  • 14. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 15. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP, Hall RR, Macaluso MP, Pawinsky A, Sylvester R, Van Glabbeke M.
    Eur Urol; 1996 Nov 15; 29(2):199-203. PubMed ID: 8647147
    [Abstract] [Full Text] [Related]

  • 16. Maintenance therapy for superficial bladder cancer.
    Baselli EC, Greenberg RE.
    Oncology (Williston Park); 2001 Jan 15; 15(1):85-8; discussion 88-91. PubMed ID: 11271984
    [Abstract] [Full Text] [Related]

  • 17. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR, Levi d'Ancona CA, Claro JF, Ilari O.
    Arch Esp Urol; 1991 Oct 15; 44(8):1025-8. PubMed ID: 1796850
    [Abstract] [Full Text] [Related]

  • 18. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
    Brosman SA.
    Urol Clin North Am; 1992 Aug 15; 19(3):557-64. PubMed ID: 1636239
    [Abstract] [Full Text] [Related]

  • 19. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M, Loertzer H, Horsch R, Keller H.
    J Urol; 2000 Jun 15; 163(6):1697-701. PubMed ID: 10799163
    [Abstract] [Full Text] [Related]

  • 20. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA, Jimenez León J, Martinez-Pineiro L, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.
    Prog Clin Biol Res; 1989 Jun 15; 310():237-52. PubMed ID: 2505269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.